In vitro transdermal permeation and in vivotransdermal absorption of domperidone cream formulations compounded from tablets as a hospital formulation

This study aimed to evaluate the transdermal absorption of domperidone cream formulations compounded from a tablet formulation. The creams were prepared to simulate hospital formulations, and skin permeation was evaluated in vitro and in vivo. In vitro steady-state permeation flux (J) values determined of each domperidone solution (19 types) was evaluated using Franz diffusion cells. Cream formulations containing 0.1% domperidone were prepared by mixing N-methyl-2-pyrrolidone (NMP) and commercially available cream bases (hydrophilic, absorptive and urea (10%)-containing cream). In vitro skin permeation of the creams was evaluated under non-occlusive and occlusive conditions. The plasma concentrations of domperidone 24 h after application of the creams were determined. The J value of NMP solution of domperidone was the highest among that of the tested solutions. The J values of the 0.1% domperidone hydrophilic and absorptive creams were lower than that of the urea-containing cream under non-occlusive conditions. However, the occlusive dressing technique (ODT) increased the J values of the hydrophilic and absorptive creams such that they were similar to that of the urea-containing cream. In in vivo absorption studies using ODT, the plasma concentrations of domperidone 24 h after application of the absorptive and urea-containing creams were 0.94±0.13 and 1.68±0.45 ng/mL, respectively. However, it was not detected after application of the hydrophilic cream. The 0.1% domperidone creams, prepared using commercially available cream bases, showed significant in vivo absorption.